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C3H/HeJ mice can be due to AA but
also is not less commonly due to
grooming behavior abnormalities
(barbering, a form of trichotillomania).
The laser comb, as used in the original
study, potentially could induce anagen
activation in the heat shock–induced
AA of the normally quiescent mouse
telogen follicles.
In summary, laser comb treatment did
not induce hair growth in C3H/HeJ mice
with extensive AA in well-established
spontaneous arising or full-thickness
skin graft mouse models of human AA.
More work on the heat shock–induced
AA model needs to be done to define its
value in preclinical trials.
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TO THE EDITOR
We thank Kottner and Streiner (2013) for
sharing their concerns, and we read
with great interest their arguments
against ‘‘dichotomizing’’ continuous
variables. We both agree and have
points of divergence with them. The
area of agreement is large, as dichot-
omizing continuous variables is gener-
ally scientifically unsound and, as
pointed out by Kottner and Streiner
(2013), leads to loss of precision, and
therefore loss of power. As a general
rule, no continuous variable should be a
priori and arbitrarily dichotomized
before being collected, and continuous
explicative variables should be kept as
such in statistical models. We therefore
want to make it clear that we are far
from defending dichotomization for
continuous variables in general.
However, outcome criteria (we exclu-
sively focused on that type of variable in
Nassar et al., (2012)) have a specific
status, and our plea for dichotomizing
clinical outcomes in dermatology may
unveil several areas of divergence with
Kottner and Streiner’s (2013) views.
Our point is that, even when an out-
come measurement uses a score based
on a continuous variable, it is valuable
to dichotomize it secondarily. For
instance, the ‘‘PASI75’’ outcome does
exactly that. ‘‘Improvement of PASI
score’’ is a continuous variable. ‘‘Has
the patient reached a threshold of 75%
improvement of his/her PASI score, yes
or no?’’ is the dichotomization of this
continuous variable. Why is defining such
a threshold and incorporating it into the
final outcome definition, in our view,
valuable and should be encouraged?
First, dichotomization of continuous vari-
ables is pervasive in our medical practice
and should not just be seen as ‘‘an
unjustified oversimplification of a complex
reality’’ but rather as a necessary simplifi-
cation. The most common dichotomization
for almost any continuous variable is
‘‘above vs. within normal range’’. Blood
pressure is a continuous variable, but set-
ting a threshold of 140/90mmHg to define
hypertension has been deemed necessary.
Many similar examples could be found.
Second, in the domain of clinical out-
comes for inflammatory skin diseases, the
apparent continuity of most scale- and
score-based outcome measurements is a
delusion. For instance, Psoriasis Area and
Severity Index (PASI) score is actually
made of elementary categorical items
(scaling, erythema, thickness) for which
quoting a number is artificial (erythema at
‘‘4’’ does not equal—and does not
mean—4 times ‘‘1’’; and no erythema
can be quoted at 5 or 4.3 in a PASI score).
Our paper, and our statements, should beAccepted article preview online 11 June 2013; pubilshed online 11 July 2013
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seen in the context of what we exclusively
focused on, i.e., clinical outcomes for
inflammatory skin diseases.
Third, we believe that results expressed
at the group level are much more mean-
ingful for the clinician if the outcome
variable has been dichotomized. We
often fail to interpret dispersion around
the mean and this inability may mislead
our judgment. Following is an example of
two presentations of the same data set.
Without dichotomization: ‘‘In group A,
PASI score had improved of 49% on
average (standard deviation: 33%)
whereas in group B, PASI score had
improved of 42% (90%)’’. With a PASI75
dichotomization: ‘‘PASI75 was achieved
by 32 (33%) in group A and 64 (67%) in
group B’’. We have of course no objec-
tion for reporting the results for both a
quantitative and qualitative parameter.
Internal validity of the trial is unaffected
by the supplementary presentation and
analysis of dichotomized outcomes.
Fourth, we agree with Kottner and
Streiner (2013) that randomized trials
should be distinguished from clinical deci-
sion-making. However, in medical prac-
tice, outcome assessment is closely related
to decision, and a decision is always, at
the end, a binary choice: ‘‘to treat or not
to treat’’, ‘‘to carry on or to stop’’, ‘‘to
increase the dose or not’’, and so on.
For all the above-mentioned reasons,
we see dichotomization of continuous
outcomes not only perfectly justifiable
in most cases but also desirable in order
to increase external validity without
altering the internal validity of clinical
trials.
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TO THE EDITOR
We read the systematic review by Nassar
et al. (2013) in the February 2013 edition
of the Journal of Investigative Derma-
tology with great interest. The need for
clear definitions, operationalizations, and
bias-free measurements of primary
outcomes in randomized controlled trials
(RCTs) in dermatology and other fields to
enhance internal and external validity of
results cannot be overemphasized. The
authors provide valuable insights that can
be used to improve RCT design and
outcome planning. However, the plea
for dichotomizing outcomes seems to be
a bit surprising. The statement ‘‘y
regardless of the disease, we believe that
attributing to the patient a binary value
conveys a general benefity’’ (Nassar
et al., 2013, p 374) and the relating
assumptions are problematic and need
to be explored further.
The obvious and widely acknowledged
limitation for dichotomizing continuous
variables is the loss of statistical power
and the loss of precision of outcome
estimates (Streiner, 2002). These are not
only ‘‘statistical drawbacks’’ (Nassar et al.,
2013, p 374), but may cause very practical
problems in clinical research practice.
Reducing the risk of type II error by
ensuring adequate power is one of the
most important quality criteria of RCTs.
When power is sacrificed owing to
dichotomizing continuous variables, this
can only be compensated by increasing
the sample size. Increasing the sample size
increases costs and study durations, which
are always a challenge in clinical research.
Sample sizes that are unnecessarily increa-
sed might also be judged unethical. The
number of participants should be mini-
mum to achieve the study objective, but
including too many subjects may cause
additional burden and may put a number
of patients at extra risks (Julious, 2004).
The assumption that ‘‘y a binary
expression is directly related to the
therapeutic decisiony’’ (Nassar et al.,
2013, p 374) might be true only in cases
where the variable by its very nature is
already a dichotomy like the presented
example of ‘‘dead’’ versus ‘‘alive’’. In all
other cases, dichotomization of a conti-
nuum is an unjustified oversimplification
of a complex reality. Dichotomizing, for
instance, cholesterol, body mass index,
transepidermal water loss, or the Derma-
tology Life Quality Index (DQLI) (Finlay
and Khan, 1994), implies that the chosen
cutoff points adequately categorize
individuals into two groups. Even if there
is consensus about this cutoff today, this
cannot be taken for granted in future.
There are various examples in medicine
and allied health sciences that, in the light
of newer evidence and insights, cutoff
values and ranges need to be adapted to
(National Heart, Lung, and Blood Institute,
2002; World Health Organization, 2006).
Far more important is the fact that catego-
rization causes artificial discontinuities.
For instance, DLQI scores ranging from
11 to 20 are interpreted as having a ‘‘very
large effect on the patient’s life,’’ and
scores ranging from 21 to 30 areAccepted article preview online 11 June 2013; published online 11 July 2013
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